---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-023199"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2026-07-09T20:08:54+00:00"
generated_at: "2026-07-09T20:10:07.039540+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q2 product sales rise 11.5% to $7.2M; domestic sales up 27.7% YoY

## Summary
- Q2 2026 total product sales $7.2M vs $6.4M in Q2 2025, an 11.5% increase.
- Domestic sales grew 27.7% to $6.2M; international sales fell 38.9% to $1.0M.
- First-half 2026 product sales $17.5M, up 20.9% from $14.5M in H1 2025.
- Tri-Shield sales up 8.3% to $4.9M; Dual-Force and other sales up 19.1% to $2.3M in Q2.
- Results are preliminary and unaudited; full Q2 earnings call scheduled for Aug 14, 2026.

## SEC filing metadata
- accession: 0001437749-26-023199
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2026-07-09T20:08:54+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000143774926023199/0001437749-26-023199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000143774926023199/iccc20260708_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-023199
- JSON: https://secwatch.observer/filing/0001437749-26-023199.json
- Plain text: https://secwatch.observer/filing/0001437749-26-023199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.